本文選題：鎂合金 + 生物材料�。� 參考：《西南大學(xué)》2017年碩士論文

【摘要】：由于在生物體內(nèi)的可降解性能,鎂合金在可降解生物材料領(lǐng)域受到越來越多的關(guān)注。其在生理介質(zhì)環(huán)境中降解的主要產(chǎn)物為鎂離子,這是一種人體必需元素,從而保證了良好的生物相容性。和傳統(tǒng)的植入材料對比,鎂合金植入材料在植入后期無需手術(shù)取出,這降低了病人身體和經(jīng)濟(jì)上的負(fù)擔(dān),同時也避免了不可降解材料在后期產(chǎn)生的炎癥等問題。在力學(xué)性能方面,鎂合金有著出色的密度小、比強(qiáng)度高比剛度高等優(yōu)點,同時,優(yōu)良的可加工性能保證了鎂合金作為植入材料該有的力學(xué)支撐性能。和傳統(tǒng)的植入材料相比,鎂合金的力學(xué)強(qiáng)度與自然骨更為接近,從而避免了傳統(tǒng)植入材料帶來的應(yīng)力屏蔽等負(fù)面影響。但是鎂合金在植入材料的應(yīng)用方向也存在著自身的缺陷-在生理介質(zhì)中的快速腐蝕,在植入材料領(lǐng)域,通常還會涉及到感染、炎癥以及血栓等問題,針對上述的問題,本文在鎂合金表面制備了藥物固載膜層的復(fù)合膜層,旨在解決快速腐蝕、感染、炎癥、血栓等問題。(1)在過去的數(shù)十年里,骨科植入手術(shù)感染的發(fā)病率已經(jīng)變得很低了,但是感染依舊是骨科植入手術(shù)中最嚴(yán)重的并發(fā)癥之一,這將導(dǎo)致治療周期的延長。植入材料表面抗生素藥物固載是解決此類問題的最佳途徑。本章節(jié)中設(shè)計了一種以AZ31鎂合金為基體,通過微波水液法制備了羥基磷灰石(HA)為底層,通過浸泡法固載抗生素硫酸慶大霉素(GS),最后通過浸漬提拉聚己內(nèi)酯(PCL)制備Mg/HAGS/PCL復(fù)合材料。微波水液法為GS的附著提供了較大的比表面積,PCL膜層的封閉作用為GS的緩慢釋放提供了可能性,PCL表面的孔狀結(jié)構(gòu)形成了藥物輸送的通道,控制了GS的釋放。電化學(xué)測試表明復(fù)合材料具有良好的耐蝕性能,在浸泡試驗中控制鎂離子的釋放。(2)植入材料服役的時候會涉及到炎癥的問題。因此文章設(shè)計了以鎂合金為基體的藥物固載的復(fù)合材料(Mg/Epoxy resin-ZnO/PCL-Ibuprofen),這種復(fù)合材料可以實現(xiàn)Mg2+和布洛芬的雙相控制釋放。復(fù)合膜層通過浸漬提拉法和噴涂法制備。復(fù)合膜層表面主要由纖維結(jié)構(gòu)組成。致密的PE-ZnO膜層,充當(dāng)物理阻攔層,抵制腐蝕介質(zhì)對鎂合金的腐蝕,提升了復(fù)合材料的耐蝕性能,同時也控制了鎂離子釋放。藥物浸泡釋放實驗表明復(fù)合膜層能夠提供約22天的藥物釋放性能。在這個階段可以有效的解決因植入材料服役初期可能引起的炎癥問題。同時,這種方法還可以應(yīng)用到其他金屬植入材料上。(3)生物可降解的藥物洗脫血管支架的發(fā)展,主要是用來解決惰性金屬材料支架引起的問題,主要有慢性炎癥以及血栓形成等風(fēng)險。鎂合金藥物溶出血管支架的研究就是生物可降解支架的一個研究方向。然而,鎂合金在生理介質(zhì)中的快速腐蝕抑制了鎂合金的應(yīng)用,另外,用來徹底解決血管疾病的多功能血管支架也需要更多的研究�；谝陨蠁栴},本實驗體系設(shè)計了Mg/MgO/PLA-FA復(fù)合材料。即在AZ31鎂合金基體上,通過在Hank’s溶液中陽極氧化制備氧化鎂膜層,之后通過浸漬提拉法制備聚乳酸-阿魏酸膜層。電化學(xué)和浸泡實驗結(jié)果表明密實的MgO/PLA-FA膜層能夠為鎂合金提供優(yōu)異的耐蝕性能。藥物浸泡溶出實驗表明復(fù)合膜層能夠提供約50天的藥物釋放功能。釋放的阿魏酸能夠降低血小板的粘附和聚集。另外,血液相容性測試表明復(fù)合材料有著很低的溶血率。這種復(fù)合材料為鎂合金血管支架的發(fā)展提供了一種可行的方案。
[Abstract]:Magnesium alloys have attracted more and more attention in the field of biodegradable materials in the field of biodegradable biomaterials. The main product of their degradation in the physiological environment is magnesium ion, which is a necessary element of human body, thus ensuring good biocompatibility. Compared with traditional implants, magnesium alloy implants are implanted in the plant. There is no need for surgical removal in the late stage, which reduces the patient's physical and economic burden, but also avoids the problem of inflammation in the late stage. In mechanical properties, magnesium alloys have excellent density, higher strength than stiffness, and excellent processability, which guarantees the magnesium alloy as an implant. Compared with the traditional implants, the mechanical strength of the magnesium alloy is closer to the natural bone, thus avoiding the negative effects of the stress shielding of the traditional implants. However, the magnesium alloy has its own defect in the direction of the application of the implanted material - the rapid corrosion in the physiological medium and the implantation. In the field of materials, infection, inflammation, and thrombus are often involved. In this paper, the composite membrane of the drug immobilized membrane is prepared on the surface of magnesium alloy, aiming at solving the problems of rapid corrosion, infection, inflammation and thrombus. (1) in the past few decades, the incidence of surgical infection in the Department of orthopedics has become very low. But infection is still one of the most serious complications in the Department of orthopedics implantation, which will lead to the prolongation of the treatment cycle. The best way to solve such problems is the immobilization of antibiotics on the surface of the implant material. In this chapter, a AZ31 magnesium alloy is designed to prepare hydroxyapatite (HA) as the bottom layer by microwave water solution. The soaking method was used to immobilizing the antibiotic gentamicin sulfate (GS). Finally, the Mg/HAGS/PCL composite was prepared by impregnating the PCL. The microwave water liquid method provided a larger specific surface area for the attachment of GS. The sealing effect of the PCL film provided the possibility for the slow release of GS, and the pore structure of the PCL surface formed the channel of drug delivery. The release of GS was made. The electrochemical test showed that the composite had good corrosion resistance and controlled the release of magnesium ions in the immersion test. (2) the problem of inflammation was involved when the implant was served. Therefore, the composite material (Mg/Epoxy resin-ZnO/PCL-Ibuprofen), based on magnesium alloy as the matrix, was designed. The material can realize the dual phase control release of Mg2+ and Bloven. The composite film is prepared by impregnation drawing and spraying. The surface of the composite film is mainly composed of fiber structure. The dense PE-ZnO film acts as a physical barrier layer, resists corrosion of the corrosion medium to magnesium alloy, improves the corrosion resistance of the composite, and controls the magnesium separation. Drug release release. The drug soaking release experiment shows that the composite membrane can provide about 22 days of drug release performance. At this stage it can effectively solve the possible inflammatory problems caused by the early stage of the implant service. At the same time, this method can also be applied to other metal implant materials. (3) biodegradable drug eluting stent Development is mainly used to solve the problems caused by inert metal material stents, mainly including chronic inflammation and thrombosis. The study of magnesium alloy drug dissolving stent is a research direction of biodegradable scaffold. However, the rapid corrosion of magnesium alloys in physiological medium inhibits the application of magnesium alloys, in addition, it is used for magnesium alloy. More research is needed for the multifunctional vascular stent to solve vascular disease. Based on the above problems, the experimental system has designed Mg/MgO/PLA-FA composite. That is, on the matrix of AZ31 magnesium alloy, the Magnesium Oxide film is prepared by anodizing in Hank 's solution, and then the polylactic acid ferulic acid film is prepared by the impregnation and drawing method. The experimental results show that the dense MgO/PLA-FA film provides excellent corrosion resistance for magnesium alloy. The drug immersion dissolution test shows that the composite film provides about 50 days of drug release. The release of ferulic acid can reduce the adhesion and aggregation of platelets. In addition, the blood compatibility test shows that the composite is very low. This composite material provides a feasible solution for the development of magnesium alloy stent.
【學(xué)位授予單位】：西南大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：TB383.2;TQ460.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 賈理男;梁成浩;黃乃寶;段峰;王利霞;;交流脈沖電沉積羥基磷灰石涂層的制備及其性能(英文)[J];稀有金屬材料與工程;2015年03期

2 吳衛(wèi);Lorenza Petrini;Lina Altomare;Silvia Farè;Rosaria Tremamunno;于振濤;Francesco Migliavacca;;可降解鎂合金支架聚合物涂層剝離的有限元模型及實驗研究(英文)[J];稀有金屬材料與工程;2014年12期

3 Lida Hou;Zhen Li;Yu Pan;Li Du;Xinlin Li;Yufeng Zheng;Li Li;;In vitro and in vivo studies on biodegradable magnesium alloy[J];Progress in Natural Science:Materials International;2014年05期

4 陳姍姍;譚麗麗;張炳春;楊柯;;聚合物涂層處理鎂合金的耐蝕性及溶血性研究[J];稀有金屬材料與工程;2014年S1期

5 Tingting Yan;Lili Tan;Bingchun Zhang;Ke Yang;;Fluoride Conversion Coating on Biodegradable AZ31B Magnesium Alloy[J];Journal of Materials Science & Technology;2014年07期

6 Hamid Reza Bakhsheshi-Rad;Mohd Hasbullah Idris;Moha mmed Rafiq Abdul Kadir;Mohammadreza Daroonparvar;;氟化處理對植入材料Mg-Ca二元合金腐蝕行為的影響(英文)[J];Transactions of Nonferrous Metals Society of China;2013年03期

7 任伊賓,楊柯,梁勇;新型生物醫(yī)用金屬材料的研究和進(jìn)展[J];材料導(dǎo)報;2002年02期

相關(guān)博士學(xué)位論文 前1條

1 李海偉;雷帕霉素涂層AZ31鎂合金支架在兔腹主動脈的初步應(yīng)用研究[D];中國醫(yī)科大學(xué);2010年

，

本文編號：1943782